Lisa Baldwin
PIONEER5: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment
People Involved
Professor Thozhukat Sathyapalan T.Sathyapalan@hull.ac.uk
Professor of Diabetes, Endocrinology and Metabolism
Project Description
Primary objective:
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus placebo, both in combination with metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin on glycaemic control in subjects with type 2 diabetes mellitus and moderate renal impairment.
Secondary objectives:
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus placebo, both in combination with metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin on body weight in subjects with type 2 diabetes mellitus and moderate renal impairment.To compare the safety and tolerability of once-daily dosing of 14 mg oral semaglutide versus placebo, both in combination with metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal insulin in subjects with type 2 diabetes mellitus and moderate renal impairment
| Type of Project | Project |
|---|---|
| Project Acronym | PIONEER5 |
| Status | Project Complete |
| Funder(s) | Novo Nordisk |
| Value | £27,085.00 |
| Project Dates | Nov 1, 2016 - Oct 31, 2019 |
You might also like
Esperion ETC 1002 Study Nov 1, 2016 - Mar 31, 2019
IVF Study 1: Does Insulin or Endocrine Disruptor levels affect fertility? Jan 1, 2014 - Dec 31, 2018
IVF Study 2: Does Insulin or Endocrine Disruptor levels affect fertility? Jan 1, 2014 - Dec 31, 2018